Canaccord Genuity analyst, Sumant Kulkarni, reiterated his Buy rating on shares of BioXcel Therapeutics (NASDAQ: BTAI) on the belief that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE